for Journalists
Pfizer Canada Inc.
Contact1: Pfizer Canada Media Relations
Phone (Bus): 1-866-973-4937
E-mail: corporate.affairs.canada@pfizer.com
Address: 17300 Trans Canada Hwy., Kirkland, PQ H9J 2M5
Web Site: www.pfizer.ca
www.pfizer.com
Keys: AIDS; Alzheimer Disease; Analgesics; Angina; Animal Health; Antibiotics; Antifungal; Anti-Inflammatory; Arthritis; Beef Industry; Calcium Channel Blockers; Cancer; Cardiovascular; Central Nervous System; Cholesterol; COPD; Depression; Diabetes; Erectile Dysfunction; Heart Disease; High Blood Pressure; HIV; HIV/AIDS Initiatives; Hypertension; Impotence; Macular Degeneration; Migraine; Neuropathic Pain; Oncology; Ophthalmology; PAH; Pain; Pets; Pharmaceutical Industry; Pharmaceuticals; Pulmonary Hypertension; Research in Canada; Respiratory; Rheumatology; Schizophrenia; Smoking Cessation; Urinary Incontinence; Urology; Veterinary Medicine.
Expertise: Research-based, global health care company active in Canada since 1953. Business segments include pharmaceuticals & animal health. Employs 2000 in Canada. International headquarters are in New York.
Pfizer's international success has been based on the strength of new products which control illness & improve quality of life.Mandate: Discover & develop innovative, value-added products that improve the quality of life of people around the world & help them enjoy longer, healthier, more productive lives.
Features: Therapeutic categories for pharmaceuticals:
· Cardiovascular
· Antibiotic
· Anti-Infective
· Dementia
· Urology
· Migraine
· Pain/Inflammation
· Arthritis
· Oncology
· Smoking Cessation
· HIV/AIDS
· Respiratory
· Ophthalmology
· Central Nervous System
Story Ideas:
2007
June 4, 2007: Putting Neuropathic Pain on the Podium; Clinicians and caregivers agree 75 to 95% of patients with Alzheimer's disease stabilize or improve over six month period for each identified symptom
May 10, 2007: Help on its way for people treated in Kabul at the CURE Hospital
May 07, 2007: Pfizer partners with Canadian policymakers to continue shaping an environment conducive to research and innovation
April 25, 2007: Health Canada Approves Lipitor for the Reduction of the Risk of Heart Attack in Patients with Coronary Heart Disease
April 17, 2007: How hard is it to quit smoking? Smokers agree that quitting would be one of their greatest accomplishments in life
March 29, 2007: New Round of Canadian Cardiovascular Research Award Recipients Announced
March 28, 2007: Pfizer is determined to be a magnet for the best science in Quebec and in the Canadian biomedical community; Lipitor Provides Unprecedented Cardiovascular Risk Reductions In Diabetes Patients With Metabolic Syndrome And In Stroke Patients
March 1, 2007: Health Canada grants priority review status to Pfizer's maraviroc, a new treatment approach for HIV
February 14, 2007: Changes to Dilantin 30mg
February 1, 2007: First New Prescription Smoking Cessation Treatment Approved In A Decade
January 31, 2007: Pfizer Canada To Streamline Pharmaceutical Operations To Improve Performance And To Better Meet Emerging Customer And Business Needs
2006
December 18, 2006: New Canadian-led study shows widely used breast cancer treatment regimen less effective at preventing recurrence of disease
December 15, 2006: Canadian patients still waiting for reimbursement of newly-approved cancer medication
December 8, 2006: Canadian Federal Court Upholds Lipitor Patent, Decision Will Prevent Launch Of Generic Product Until 2010
December 4, 2006: In Interests of Patient Safety, Pfizer Stops All Torcetrapib Clinical Trials; Company Has Notified FDA and Is In The Process of Notifying All Clinical Investigators and Other Regulatory Authorities
November 28, 2006: National Research Project to Improve Drug Safety In Children Receives $500,000 Grant from Pfizer Canada Inc.
October 10, 2006: HPIC Honours Pfizer Canada For Donating More Than $27 Million Worth Of Medicines
September 22, 2006: Pfizer Commits $15 Million Through President Clinton's Global Initiative To Address Critical Treatment Gaps In Malaria
September 12, 2006: Quebec Sports and Physical Activity Day
September 8, 2006: Health Canada approves SUTENT* for metastatic kidney cancer; Landmark Study Shows Patients Taking A Regimen Based On Pfizer's Norvasc® (Amlodipine Besylate) Have A Reduced Risk Of Developing Diabetes
August 30, 2006: Pfizer to exit operations in Arnprior by 2008
August 22, 2006: Revatio approved to treat rare and incurable disease
August 21, 2006: New Study of Patients with Advanced HIV-1 Infections Provides Insight on the Investigational CCR5 Antagonist, Maraviroc
August 15, 2006: HIV/AIDS Initiatives - Media Update
August 10, 2006: Pfizer's Lipitor Shown to reduce the chance of additional strokes in stroke patients
June 12, 2006: Canadian Cardiovascular Research Award Recipients Announced
June 5, 2006: Better Survival Seen For Women With Early Breast Cancer Who Switched From Tamoxifen To Pfizer's Aromasin® (exemestane tablets)
May 31, 2006: Health Canada approves Pfizer's multi-targeted agent SUTENT; therapy meets unmet need in difficult-to-treat cancer
May 24, 2006: Media Release - Pfizer Canada Makes Significant Contribution to NOSM's Virtual Medical Resource Library
May 17, 2006: Aromasin Becomes The First And Only Aromatase Inhibitor For Adjuvant Sequential Therapy In Early-Stage Breast Cancer
May 10, 2006: Improved health of employees and financial bottom line demonstrated through innovative pilot program at DaimlerChrysler Canada's Windsor Assembly Plant
May 8, 2006: Pfizer Statement - 1996 Trovan Clinical Study In Nigeria
March 17, 2006: MACUGENTM Represents a Substantial Improvement in the Treatment of Age-Related Macular Degeneration; Boomers in the Bedroom - Sexual Attitudes, Thoughts and Behaviours of the Boomer Generation
March 6, 2006: Pfizer Canada Cheers On Its Sixth Canadian Paralympic Team,
Marking 10 Years Of Leading Corporate Sponsorship As Elite Athletes With A Disability Prepare To Head For Turin
March 2, 2006: National Report Card Reveals Antibiotic Resistance And Antibiotic Prescriptions On The Rise
February 14, 2006: Caduet, First Pill to Treat High Blood Pressure and High Cholesterol at the same time
January 26, 2006: Making The ConnectionT : The Heart And Stroke Foundation Joins Partnership To Help Canadians Control Cholesterol
January 18, 2006: Capital Health receives $750,000 donation from Pfizer
January 13, 2006: Pfizer To Acquire The Sanofi-Aventis Worldwide Rights To Exubera® (Inhaled Human Insulin)
updated: July 31, 2007